- Home
- BNT vs PEN Comparison
BNT vs PEN Comparison
Compare BNT & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNT | PEN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BNT | PEN |
|---|---|---|
| Price | $47.76 | $315.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $332.40 |
| AVG Volume (30 Days) | 16.9K | ★ 441.4K |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | 0.15 | ★ 367.34 |
| EPS | ★ 4.29 | 4.14 |
| Revenue | ★ $14,328,000,000.00 | $1,333,798,000.00 |
| Revenue This Year | N/A | $16.77 |
| Revenue Next Year | N/A | $14.12 |
| P/E Ratio | ★ $11.11 | $76.40 |
| Revenue Growth | ★ 35.36 | 14.61 |
| 52 Week Low | $29.13 | $221.26 |
| 52 Week High | $49.86 | $321.38 |
Technical Indicators
Market Signals| Indicator | BNT | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 59.78 |
| Support Level | $45.95 | $305.30 |
| Resistance Level | $49.86 | $320.42 |
| Average True Range (ATR) | 0.85 | 7.82 |
| MACD | 0.29 | -1.48 |
| Stochastic Oscillator | 59.14 | 64.77 |
Price Performance
Historical ComparisonAbout BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. It is organized into three reporting segments: Direct Insurance, Reinsurance, and Pension Risk Transfer (PRT).
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.